Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 19;21(6):549–559. doi: 10.1080/15384047.2020.1737490

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 4. — In vivo assessment of lead P3D12 cMet ADC.

(a) Time concentration curves of P3D12 and P3D12-vc-MMAF and their pharmacokinetic parameters in mice. C57BL/6 mice were injected via the vein with 1 mg/kg P3D12 and P3D12-vcMMAF. Plasma samples were analyzed by ELISA to determine the antibody or antibody-drug conjugate concentration. Pharmacokinetic parameters of P3D12 and P3D12-vc-MMAF antibody-drug conjugate were calculated with WinNonlin software. (b) Antitumor activity of P3D12 and P3D12-vc-MMAF in the high c-Met gastric cancer xenograft model MKN-45. P3D12 unconjugated antibody was administered intravenously at 10.0 mg/kg and P3D12-vcMMAF at 3.0, 5.0, and 10.0 mg/kg and compared to the control ADC Rituximab-vc-MMAF (Rituxan®: Rituximab, 10.0 mg/kg). Group size n = 9, Tumor volume was plotted as mean ± S.E.M. Statistical significance was determined with a two-way ANOVA followed by Bonferroni post hoc test (**** p < .0001 compared to control). (c) Antitumor activity of P3D12 and P3D12-vc-MMAF in low-medium c-Met lung cancer xenograft model H1975 with L858 R/T790 M-EGFR mutations. P3D12 unconjugated antibody was administered intravenously at 10.0 mg/kg and P3D12-vc-MMAF was at 3.0, 5.0, and 10.0 mg/kg and compared with the control ADC Rituximab-vc-MMAF (Rituxan®: Rituximab, 10.0 mg/kg). Group size n = 9, Tumor volume was plotted as mean ± S.E.M. 9 mice per group were used for the H1975 studies. Statistical significance was determined with a two-way ANOVA followed by Bonferroni post hoc test (**** p < .0001 compared to control).